Results     07-Nov-23
Analysis
Divis Laboratories
NP down 29.41%
For the quarter ending Sept 2023, consolidated Net sales (including other operating income) of Divis Laboratories has increased 2.91% to Rs 1909 crore compared to quarter ended Sept 2022.
Operating profit margin has declined from 33.48% to 25.09%, leading to 22.87% decline in operating profit to Rs 479.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 40.79% to 39.28%.   Employee cost increased from 11.58% to 14.70%.   Other expenses rose from 16.33% to 19.56%.   

Other income rose 7.50% to Rs 86 crore.  PBIDT fell 19.40% to Rs 565 crore.  Provision for interest remained nil.  

PBDT fell 19.54% to Rs 564 crore.  Provision for depreciation rose 10.47% to Rs 95 crore.  

Profit before tax down 23.74% to Rs 469.00 crore.  Share of profit/loss were nil in both the periods.  Provision for tax was expense of Rs 121 crore, compared to Rs 122 crore.  Effective tax rate was 25.80% compared to 19.84%.

Minority interest was nil in both the periods.  Net profit attributable to owners of the company decreased 29.41% to Rs 348.00 crore.  

Promoters’ stake was 51.93% as of 30 September 2023 ,compared to 51.94% as of 30 September 2022 .  

For year-to-date (YTD) results analysis.

Net sales (including other operating income) of Divis Laboratories has declined 10.27% to Rs 3687 crore.  

Operating profit margin has declined from 35.73% to 26.66%, leading to 33.04% decline in operating profit to Rs 983.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 37.75% to 41.30%.   Employee cost increased from 11.31% to 14.19%.   Other expenses rose from 15.99% to 18.16%.   

Other income fell 1.18% to Rs 167 crore.  PBIDT fell 29.75% to Rs 1150 crore.  

PBDT fell 29.77% to Rs 1149 crore.  Provision for depreciation rose 11.24% to Rs 188 crore.  

Profit before tax down 34.49% to Rs 961.00 crore.  Share of profit/loss were nil in both the periods.  Provision for tax was expense of Rs 257 crore, compared to Rs 271 crore.  Effective tax rate was 26.74% compared to 18.47%.

Minority interest was nil in both the periods.  Net profit attributable to owners of the company decreased 41.14% to Rs 704.00 crore.  

Promoters’ stake was 51.93% as of 30 September 2023 ,compared to 51.94% as of 30 September 2022 .  


Full year results analysis.

Net sales (including other operating income) of Divis Laboratories has declined 13.31% to Rs 7767 crore.  Operating profit margin has declined from 43.33% to 30.49%, leading to 39% decline in operating profit to Rs 2,368.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 36.66% to 38.84%.   Purchase of finished goods cost rose from 0.15% to 0.28%.   Employee cost increased from 9.98% to 12.59%.   Other expenses rose from 12.28% to 17.70%.   

Other income rose 202.98% to Rs 345 crore.  PBIDT fell 32.10% to Rs 2713 crore.  Provision for interest rose 25% to Rs 1 crore.  Loan funds declined from Rs 3.69 crore as of 31 March 2022 to Rs 3.26 crore as of 31 March 2023.  Inventories rose to Rs 3,000.41 crore as of 31 March 2023 from Rs 2,828.62 crore as of 31 March 2022.  Sundry debtors were lower at Rs 1,792.53 crore as of 31 March 2023 compared to Rs 2,423.88 crore as of 31 March 2022.  Cash and bank balance rose to Rs 4,213.09 crore as of 31 March 2023 from Rs 2,818.88 crore as of 31 March 2022.  Investments rose to Rs 77.05 crore as of 31 March 2023 from Rs 72.01 crore as of 31 March 2022 .  

PBDT fell 32.12% to Rs 2712 crore.  Provision for depreciation rose 10.11% to Rs 343 crore.  Fixed assets increased to Rs 4,929.20 crore as of 31 March 2023 from Rs 4,787.49 crore as of 31 March 2022.  Intangible assets declined from Rs 7.49 crore to Rs 5.28 crore.  

Profit before tax down 35.69% to Rs 2,369.00 crore.  Share of profit/loss were nil in both the periods.  Provision for tax was expense of Rs 545 crore, compared to Rs 723.05 crore.  Effective tax rate was 23.01% compared to 19.63%.

Minority interest was nil in both the periods.  Net profit attributable to owners of the company decreased 38.39% to Rs 1,824.00 crore.  

Equity capital stood at Rs 53.09 crore as of 31 March 2023 to Rs 53.09 crore as of 31 March 2022.  Per share face Value remained same at Rs 2.00.  

Promoters’ stake was 51.94% as of 31 March 2023 ,compared to 51.94% as of 31 March 2022 .  

Cash flow from operating activities increased to Rs 2,459.73 crore for year ended March 2023 from Rs 1,911.80 crore for year ended March 2022.  Cash flow used in acquiring fixed assets during the year ended March 2023 stood at Rs 473.02 crore, compared to Rs 713.20 crore during the year ended March 2022.  

Other highlights

In Q2 FY24, company had a forex gain of Rs 11 crore as against a gain of Rs 31 crore during the corresponding quarter of last year.


Divis Laboratories : Consolidated Results
 Quarter endedYear to DateYear ended
Particulars202309202209Var.(%)202309202209Var.(%)202303202203Var.(%)
Net Sales (including other operating income)1,909.001,855.002.913,687.004,109.00-10.277,767.008,959.83-13.31
OPM (%)25.0933.48-839 bps26.6635.73-907 bps30.4943.33-1,284 bps
OP479.00621.00-22.87983.001,468.00-33.042,368.003,881.94-39.00
Other Inc.86.0080.007.50167.00169.00-1.18345.00113.87202.98
PBIDT565.00701.00-19.401,150.001,637.00-29.752,713.003,995.81-32.10
Interest1.000-1.001.0001.000.8025.00
PBDT564.00701.00-19.541,149.001,636.00-29.772,712.003,995.01-32.12
Depreciation958610.4718816911.24343311.5110.11
PBT469.00615.00-23.749611467-34.4923693683.5-35.69
Share of Profit/(Loss) from Associates00-00-00-
PBT before EO469615-23.749611467-34.4923693683.5-35.69
EO Income00-00-00-
PBT after EO469615-23.749611467-34.4923693683.5-35.69
Taxation121122-0.82257271-5.17545723.05-24.62
PAT348493-29.417041196-41.1418242960.45-38.39
Minority Interest (MI)00-00-00-
Net profit348493-29.417041196-41.1418242960.45-38.39
P/(L) from discontinued operations net of tax00-00-00-
Net profit after discontinued operations348493-29.417041196-41.1418242960.45-38.39
EPS (Rs)*13.1118.57-29.4126.5245.05-41.1468.71111.52-38.39
* EPS is on current equity of Rs 53.09 crore, Face value of Rs 2, Excluding extraordinary items.
# EPS is not annualised
bps : Basis points
EO : Extraordinary items
Figures in Rs crore
Source: Capitaline Corporate Database


Previous News
  Divis Laboratories Ltd up for third straight session
 ( Hot Pursuit - 05-Sep-24   13:05 )
  Divis Lab Q4 PAT drops 64% YoY; declares dividend of Rs 30/share
 ( Hot Pursuit - 20-May-23   14:59 )
  Divis Laboratories Ltd spurts 3.19%, up for third straight session
 ( Hot Pursuit - 26-Dec-23   13:05 )
  Board of Divis Laboratories recommends Final Dividend
 ( Corporate News - 25-May-24   12:57 )
  Divis Laboratories
 ( Results - Analysis 23-May-22   15:02 )
  Divi's Laboratories standalone net profit declines 63.90% in the March 2023 quarter
 ( Results - Announcements 20-May-23   14:28 )
  Divis Laboratories Ltd soars 0.23%, up for fifth straight session
 ( Hot Pursuit - 12-Mar-24   13:00 )
  Divis Laboratories to convene AGM
 ( Corporate News - 25-May-24   15:16 )
  Divis Laboratories Ltd rises for third straight session
 ( Hot Pursuit - 21-Aug-24   13:05 )
  Nifty April futures trade at premium
 ( Market Commentary - Futures Market 12-Apr-23   16:21 )
  Divi's Laboratories consolidated net profit declines 64.12% in the March 2023 quarter
 ( Results - Announcements 20-May-23   14:28 )
Other Stories
  Yes Bank
  19-Apr-25   21:23
  Mastek
  19-Apr-25   09:49
  Tata Elxsi
  18-Apr-25   05:58
  Infosys
  18-Apr-25   05:13
  HDFC Life Insurance Company
  18-Apr-25   08:47
  Wipro
  17-Apr-25   06:04
  Swaraj Engines
  16-Apr-25   20:29
  ICICI Lombard General Insurance Company
  16-Apr-25   08:50
  ICICI Prudential Life Insurance Company
  15-Apr-25   23:58
  Tata Consultancy Services
  11-Apr-25   05:46
Back Top